Strata Critical Medical Inc Class (SRTA) valuation
Strata Critical Medical Inc Class P/E ratio history
Strata Critical Medical Inc Class trades at 8.9 times its earnings over the last twelve months.
| Fiscal year ended | Price | EPS | P/E |
|---|---|---|---|
| Dec 31, 2025 | $4.81 | $0.50 | 9.6 |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Strata Critical Medical Inc Class valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Strata Critical Medical Inc ClassSRTA | $384M | 8.9 | — | 1.5 |
| RezoluteRZLT | $380M | — | — | — |
| Alpha TeknovaTKNO | $395M | — | — | 9.0 |
| Tectonic TherapeuticTECX | $373M | — | — | — |
| RegenxbioRGNX | $372M | — | — | 2.1 |
| AltimmuneALT | $397M | — | — | — |
| Shoulder InnovationsSI | $397M | — | — | 6.6 |
| EmbectaEMBC | $371M | 4.3 | 3.5 | 0.4 |
| Viemed HealthcareVMD | $371M | 26.9 | 20.2 | 1.2 |
| Peer median | 15.6 | 11.9 | 2.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: SRTA financials · SRTA returns
No forecast, no recommendation. This page describes Strata Critical Medical Inc Class from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.